文献速递眼底病与葡萄膜炎神经眼科

马拉维若通过调控CCL5/CCR5/CTSS轴预防视神经损伤诱导的视网膜神经节细胞凋亡

Maraviroc Prevents Optic Nerve Injury-Induced Retinal Ganglion Cell Apoptosis by Modulating the CCL5/CCR5/CTSS Axis.
PubMed 文献 · Invest Ophthalmol Vis Sci · 2025-01-01

本研究通过生物信息学分析发现CCR5是与急慢性视网膜神经节细胞(RGC)损伤相关的关键基因,并在视神经夹伤(ONC)动物模型中评估CCR5抑制剂马拉维若的神经保护作用;结果显示马拉维若可保护RGC结构、维持神经节细胞复合体(GCC)厚度并改善视网膜功能,其机制涉及防止组织蛋白酶S(CTSS)下调和神经元凋亡,玻璃体内注射马拉维若具有安全性。

要点

  • 生物信息学分析提示CCR5与急慢性RGC损伤相关。
  • 马拉维若在ONC模型中保护RGC结构、维持GCC厚度并改善视网膜功能。
  • 玻璃体内注射马拉维若在未损伤眼安全,并减少ONC损伤眼的RGC损伤。

核心结论

  • 青光眼中的小胶质细胞激活上调CCL5,通过CCR5介导的CTSS下调触发RGC凋亡。
  • 马拉维若有效减少RGC死亡和视神经损伤,为视神经损伤治疗提供有前景的神经保护策略。

研究设计与样本

  • 研究为动物实验,使用视神经夹伤(ONC)模型评估马拉维若或sh-Ccr5的神经保护作用。
  • 对青光眼数据集GSE142881和GSE26299进行生物信息学分析。
  • 采用免疫荧光、TUNEL染色、光学相干断层扫描(OCT)和电生理检查进行评估。
  • 将神经2a细胞与激活的BV2细胞共培养以探讨机制。
  • 通过组织学和分子学检测评估玻璃体内注射马拉维若的安全性和有效性。

主要发现

  • CCR5在两个数据集中均与RGC损伤显著相关。
  • 在ONC模型中,马拉维若抑制CCR5可保护RGC结构、维持GCC厚度并改善视网膜功能。
  • CCR5抑制可防止ONC或激活小胶质细胞诱导的CTSS下调和神经元凋亡。
  • 玻璃体内注射马拉维若安全,在未损伤眼保留视网膜结构和RGC计数,在ONC损伤眼减少RGC损伤。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Optic nerve crush (ONC) is an animal model that induces optic nerve injury and retinal ganglion cell (RGC) death, which is partly mediated by activated microglia secreting cytokines. This study explores the role of the CCL5/CCR5 pathway in RGC damage and evaluates maraviroc, a CCR5 inhibitor, as a potential therapeutic agent. METHODS: Bioinformatic analysis of glaucoma datasets (GSE142881 and GSE26299) identified Ccr5 as a key gene linked to acute or chronic RGC injury. The ONC model was used to evaluate the neuroprotective effects of maraviroc or sh-Ccr5 using immunofluorescence, TUNEL staining, optical coherence tomography (OCT), and electrophysiological tests. Co-culture of neuro2a cells with activated BV2 cells examined mechanisms, and intravitreal maraviroc safety and efficacy were evaluated using histological and molecular assays. RESULTS: CCR5 was significantly associated with RGC injury in both datasets. Inhibition of CCR5 via maraviroc preserved RGC structure, maintained ganglion cell complex (GCC) thickness, and improved retinal function in the ONC model. Mechanistically, CCR5 inhibition prevented Cathepsin S (CTSS) downregulation and neuron apoptosis induced by ONC or activated microglia. Intravitreal maraviroc administration was safe, preserving retinal structure and RGC count in non-injured eyes while reducing RGC damage in ONC-injured eyes. CONCLUSIONS: Microglial activation in glaucoma upregulates CCL5, triggering CCR5-mediated RGC apoptosis via CTSS downregulation. Maraviroc effectively reduces RGC death and optic nerve damage, offering a promising neuroprotective strategy for treatment of optic nerve injury.

来源:Invest Ophthalmol Vis Sci,查看原文。版权归原作者所有。

引用

  1. Huang J, Chang Z, Liu L, et al. Maraviroc Prevents Optic Nerve Injury-Induced Retinal Ganglion Cell Apoptosis by Modulating the CCL5/CCR5/CTSS Axis. Invest Ophthalmol Vis Sci. 2025. PMID: 40557874. doi:10.1167/iovs.66.6.77

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。